Orders

Search documents
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
Prnewswire· 2025-06-30 06:00
Core Insights - Klotho Neurosciences, Inc. is advancing the manufacturing and process development for KLTO-202, a gene therapy aimed at treating amyotrophic lateral sclerosis (ALS) [1] - The company has licensed a unique RNA splice variant of the alpha-Klotho gene from the Autonomous University of Barcelona, which is crucial for developing gene therapies [2] - Animal studies have shown that amplifying the levels of secreted alpha-Klotho (s-KL) through gene therapy leads to favorable therapeutic outcomes in models of ALS and other neurodegenerative diseases [2] - The company anticipates an eight-month timeline to complete process development and manufacturing, followed by four to six months for FDA-related activities, aiming to start clinical trials in ALS patients by Q3 of the following year [3] - The CEO highlighted a more efficient method for producing the AAV vector to deliver the s-KL gene directly to motor neurons, which are significantly affected by ALS [4] Company Overview - Klotho Neurosciences, Inc. focuses on innovative cell and gene therapies derived from the human Klotho gene, targeting neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease [5] - The company's portfolio includes proprietary cell and gene therapy programs utilizing DNA and RNA therapeutics, along with genomics-based diagnostic assays [5] - The management team consists of experienced individuals in biopharmaceutical product development and commercialization [5]
Rep. Jamie Raskin: The Supreme Court has 'unleashed chaos' with birthright citizenship ruling
MSNBC· 2025-06-29 00:03
Democrats in Congress are slamming the Supreme Court's ruling in the birthright citizenship case. Our next guest, Democratic Congressman Jamie Raskin, wrote on X, "Eager to sue Trump's wounded ego, the Supreme Court ended nationwide injunctions. Trump is crowing, but this is this just means we'll take our smashing wins in four district courts and turn them into wins in 94 district courts. People born here are citizens, period." Ranking member on the House Judiciary Committee, Congressman Jamie Rascin joins ...
US Economy: Jobless Claims Fall, 1Q GDP Revised to -0.5%
Bloomberg Television· 2025-06-26 14:22
Durable goods orders on a headline basis hasn't crossed yet, but ex transportation up half a percent. The capital goods orders not defense ex air, what we call core durables up 1.7% after falling 1.5% last month. So this is good news.Business is still spending. We will have to see what the breakdown is there. Here's jobless claims.They fall to 236,000 from 246,000 last month. Last week there were a lot of people who thought this may be a seasonal adjustment problem. That pushed claims up in recent weeks bec ...
Jobless claims fall, GDP revised lower, durables orders soar
CNBC Television· 2025-06-26 13:14
Rick Santelli is standing by at the CME in Chicago. And uh Rick, take it away. Let's see the numbers.Yes. And there are a lot of numbers, so we're going to go slow. And let's start with well, let's start with durable goods, shall we.On durable good orders, we're expecting a number that's going to be somewhere in the vicinity of up 8 to 8 and a half% on a preliminary, not coming across the screen. So, we're going to switch gears. We're going to look at the trade balance minus 96.6% billion.So the good news t ...
California Nanotechnologies Announces FY2025 Results
Newsfile· 2025-06-26 11:00
Core Insights - California Nanotechnologies Corp. reported revenues of US$6,224,738 for the fiscal year ending February 28, 2025, marking an 87% increase from the previous year [1] - The company experienced a net loss of US$158,333, a significant decline from a net income of US$381,678 in the prior fiscal year, primarily due to non-cash charges related to share purchase warrants [2] - Adjusted EBITDA for the fiscal year was US$2,558,515, a substantial increase of 121% compared to US$1,157,141 in the previous year [6][12] Financial Performance - Revenues for the fiscal quarter ended February 28, 2025, were US$1,147,522, representing a 17% increase year-over-year [6] - Gross margin for the fiscal year was 74%, an improvement from 70% in the previous year, attributed to operational efficiencies [5][12] - The company reported cash flow from operations of US$2,923,881, a dramatic increase of 2,704% compared to US$104,284 in the prior year [12] Business Strategy and Outlook - The CEO stated that the company is entering a new phase aimed at creating predictable and scalable revenues through recurring commercial orders [4] - The company has made significant investments in personnel and equipment, totaling over US$2 million in FY2025, to support future growth [8] - The company aims to diversify its revenue streams and reduce reliance on a single customer, particularly in light of reduced activity from its green steel customer [9][10] Operational Highlights - The increase in revenue was primarily driven by manufacturing services, which generated US$5,316,068, and Spark Plasma Sintering (SPS) equipment deliveries, contributing US$908,670 [4] - The company has improved its balance sheet by fully repaying borrowings from Omni-Lite Industries Canada Inc., enhancing its financial flexibility [11] - The company anticipates fluctuations in gross margin based on the mix of manufacturing services and equipment sales [5]
NSC Invests $300,000 in Next-Generation Solutions for Safer Workplaces
Prnewswire· 2025-06-25 19:02
Core Insights - The National Safety Council (NSC) awarded $300,000 in grants for the 2025-2026 Research to Solutions (R2S) and MSD Solutions Pilot programs, totaling nearly $850,000 invested in musculoskeletal disorders (MSDs) prevention over three years [1][2] Group 1: Grant Programs - The grants support academic research and workplace pilot programs through the NSC MSD Solutions Lab, which was established in 2021 with funding from Amazon [2][6] - The R2S grant provides up to $50,000 for academic institutions to explore innovative MSD interventions, focusing on areas like emerging technologies and total worker wellbeing [4][5] - The MSD Solutions Pilot Grant offers $20,000 to trial safety innovations through partnerships between MSD Pledge members and technology providers [5][7] Group 2: Awardees and Projects - University of Waterloo will utilize innovative MSD risk assessment tools leveraging data from emerging technologies [7] - Auburn University plans to test a new plant-layout organizational tool for MSD control [7] - Texas Tech University will assess 3D printed head and neck rests to reduce discomfort during overhead work [7] - George Mason University aims to develop smartphone computer vision technology for real-time movement assessment to prevent MSDs in emergency responders [7] - Cargill will collaborate with MākuSafe to explore technology for risk profiling and early hazard identification [7] - Northwell will validate the benefits of a "surgeon exoskeleton" in reducing upper limb strain during complex surgical procedures [7]
Here's Why Airbus Shares Took Off Today
The Motley Fool· 2025-06-20 19:33
Group 1 - Airbus shares rose by up to 3.1% following the Paris Air Show, where the company announced $21 billion in orders [1][3] - Boeing scaled down its participation at the air show and did not announce new orders due to a recent crash involving a Boeing 787 Dreamliner [2] - Airbus announced $14.2 billion in firm orders and an additional $6.7 billion under memoranda of understanding (MoUs) [3] Group 2 - Among the firm orders, LOT Polish Airlines made its first-ever order for 40 A220 aircraft, while All Nippon Airways ordered 27 A321 airplanes [4] - Riyadh Air ordered 25 A350 wide-body aircraft, marking it as the first Saudi airline to operate the A350 [4] - VietJet signed an MoU for 100 Airbus A321neo aircraft, indicating strong demand for Airbus products [4] Group 3 - The strength in A350 and A321 orders reflects a positive trend for Airbus, especially as it competes with Boeing [6] - The 40 A220 orders signify a recovery for a model that had seen limited deals in the past year [6] - Overall, the air show was a success for Airbus, positively impacting its stock price [6]
Airbus orders dominate Paris Air Show as Boeing takes backseat — again
CNBC· 2025-06-19 14:10
Core Insights - Airbus has dominated the Paris Air Show with nearly $21 billion in orders, significantly outpacing Boeing's 41 orders and Embraer's 15 orders [2][3] - Boeing's subdued presence is attributed to ongoing challenges, including the recent Air India crash and quality control issues, rather than a decline in demand [11][12][15] - The overall demand for new aircraft remains strong, driven by passenger demand and the need for airlines to renew aging fleets [10][13][16] Airbus Performance - Airbus secured 132 firm orders on Monday, including significant deals with AviLease, ANA, and LOT, and a 150-aircraft Memorandum of Understanding with VietJet Air [2][3] - The company is experiencing strong demand for wide-body aircraft, which are recovering more slowly than narrow-body models post-pandemic [15] Boeing's Situation - Boeing's quiet approach at the air show is a strategic decision amid a volatile geopolitical backdrop and recent crises, including the Air India disaster [11][12][15] - Despite fewer announcements, Boeing has a backlog of over 5,000 aircraft, indicating sustained demand in the long term [9][10] Industry Demand - The aircraft manufacturing industry is facing strong demand, with both Boeing and Airbus having backlogs that have remained stable for nearly a decade [9][10] - Stakeholders are cautious in the current environment, aware of the implications of any relaxation of safety standards following recent incidents [13][14] Market Context - The air show reflects a "muted" atmosphere in commercial aviation, with defense contracts gaining prominence due to geopolitical tensions [14] - Airlines are reassessing fleet strategies in light of recent crises, but strong profitability and travel demand growth suggest a continued appetite for new aircraft [16]
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
MarketBeat· 2025-06-12 17:58
Industry Overview - The biopharmaceuticals industry presents both exciting opportunities and significant risks for investors, with leading growth stocks often emerging from this sector due to substantial rallies following positive trial results or government drug approvals [1][2] - Many biopharma firms face constant threats of collapse due to insufficient revenue, making breakthrough developments critical for their survival [2] Investment Strategies - Investors can balance their risk tolerance by relying on Wall Street analysts who specialize in the healthcare sector, potentially identifying high-potential investments before they gain mainstream recognition [3] Company Highlights: Kymera Therapeutics - Kymera Therapeutics Inc. focuses on developing small-molecule therapeutics to selectively degrade disease-causing proteins, with positive Phase 1 trial results for its flagship drug KT-621, aimed at treating moderate to severe atopic dermatitis [4][6] - The stock forecast for Kymera indicates a 12-month price target of $59.82, representing a 25.65% upside from the current price of $47.61, with 17 out of 18 analysts rating it as a Buy [5][7] - Kymera benefits from a robust pipeline and a partnership with AI-powered biopharma developer Sanofi, along with substantial cash reserves expected to sustain operations through 2028 [7] Company Highlights: Vera Therapeutics - Vera Therapeutics Inc. specializes in treatments for immunological diseases, with its leading candidate atacicept recently completing a positive Phase 3 trial for IgAN, positioning the company for potential FDA approval and a commercial launch by 2026 [9][10] - The stock forecast for Vera suggests a 12-month price target of $65.00, indicating a 193.45% upside from the current price of $22.15, with 9 out of 10 analysts rating it as a Buy [10][12] Company Highlights: Rapport Therapeutics - Rapport Therapeutics Inc. develops medicines for neurological and psychiatric disorders, with its candidate RAP-219 showing positive trial data for refractory focal epilepsy and plans for trials in bipolar mania [13][14] - The stock forecast for Rapport indicates a 12-month price target of $32.67, representing a 191.41% upside from the current price of $11.21, with all four analysts rating it as a Buy [14][15]
New Findings from NSC Grant Recipients Help Tackle America's Most Common Workplace Injury
Prnewswire· 2025-06-11 19:00
Core Insights - The MSD Solutions Lab, established by the National Safety Council (NSC) in 2021 with funding from Amazon, aims to reduce musculoskeletal disorders (MSDs) through innovative research and pilot programs [2][4] - The 2023-2024 MSD Solutions Lab Research to Solutions (R2S) and Pilot Grant programs have shown measurable progress in addressing MSDs, which are the most common workplace injuries [1][3] Funding and Grants - Nearly $850,000 has been awarded by NSC in the third grant cycle, including $275,000 to nine organizations during the inaugural 2023-2024 cycle [2] - The MSD Solutions Pilot Grant program supported various companies, including Amerisure Insurance and General Electric Aerospace, in applying emerging technologies to manual materials handling [3] Technological Innovations - The pilot programs involved trials with HeroWear, an exosuit developer, and TuMeke Ergonomics, which utilizes computer vision to detect risky postures [3][6] - Rutgers University developed an AI-based image captioning tool for real-time ergonomic risk identification, while Iowa State University created a predictive model for shoulder MSD hazards [6] Industry Collaboration - The initiative emphasizes collaboration across industries to effectively address MSDs through strategic investment and innovative thinking [4] - NSC's efforts include providing data-backed insights on emerging safety technologies to reduce ergonomic risks [4]